SCIEX, a global leader in life science analytical technologies, and EVOSCIENCES, a world leader in management of high technology equipment, announced today that SCIEX mass spectrometry systems are now available to purchase through a wide range of flexible financing packages.

With these financing packages, SCIEX equipment is now accessible to a broader range of customers including those with limited or short-term mass spectrometry needs. The financing packages will also allow for greater flexibility meaning customers will easily be able to change from a previous contract and upgrade to new SCIEX technologies when they become available. The agreement with EVOSCIENCES enables analytical scientists working across all application areas, including life science research, pharmaceuticals, biologics, forensics, food testing and environmental analysis, to optimise the lifecycle of their SCIEX equipment.

The traditional methods of financing available to scientists such as financial leasing, bank loans and capital investment, may not satisfy their requirements. There is a need for scientists to have access to more innovative finance tools that allow lease periods to be recalculated in terms of actual use as opposed to the depreciation of equipment. The offering through EVOSCIENCES can provide flexible finance tools to make the following services available to SCIEX customers, all directly through EVOSCIENCES: standard financing offers, deferred payments, deposit or pre-paid leasing, and short-term financing. Deferred payments will allow customers to obtain the equipment they need and pay the cost at a later date. Short-term leases that are between six and 12 months long can also be available, which is a useful finance tool for contract research organisations. Start-up programmes may also be offered by EVOSCIENCES for smaller companies. Special offers are currently available on LC-MS bundles and EVOSCIENCES can offer deals suited to customers’ specific applications.

"We have built a strong and trusting relationship with SCIEX over the last ten years and we are delighted to formalise the relationship with this financing arrangement. We combine our deep expertise in financing life science equipment together with SCIEX’s world-class technology, to provide scientists with flexible financial solutions suited for all their laboratory needs,” said Ludwig Kubacki, European Sales Manager, EVOSCIENCES. “Our arrangement with SCIEX will also allow us to extend our own customer base, and grow our portfolio.”

“The arrangement with EVOSCIENCES allows them to offer adapted financial solutions to our customers and make sure that customers have access to our latest solutions for their laboratories,” said Marco Eijsackers, Vice President and General Manager, EMEAI, SCIEX. “We are looking forward to continuing to enable scientists with their research, through such flexible offerings.”

The financing packages will be available on all SCIEX LC-MS technologies, including the QTRAP^® 6500+ System that features the multi-component IonDrive™ Technology and is enhanced with an IonDrive High Energy Detector+, and the TripleTOF^® 6600 System, which delivers high performance and reproducibility that can detect virtually every peptide in every run when executing SWATH^® Acquisition 2.0. Data independent acquisition using SWATH is the deepest and most comprehensive mass spectrometry acquisition in the world; there is no other technique on the market that can do what SWATH can.

These financing packages are currently available for SCIEX equipment in the following countries: France, Italy, Spain, Germany, UK, Benelux, Austria, and Switzerland.

more about SCIEX